IRD Opus Genetics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: IRD

Price (delayed)

$4.83

Market cap

$401.84M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.29

Enterprise value

$347.86M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 95
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 19

Rexahn Pharmaceuticals, Inc. is a biotechnology company that has been focused on the development of innovative therapies to improve patient outcomes in cancers that are difficult to treat.

Highlights
The quick ratio has soared by 77% from the previous quarter
The company's EPS rose by 33% YoY and by 3% QoQ
Opus Genetics's equity has shrunk by 174% YoY but it has surged by 72% QoQ
The company's net income has shrunk by 85% YoY
IRD's gross profit is down by 36% YoY and by 18% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rexahn.com
Peers: OPK ORGO

Key stats

What are the main financial stats of IRD

IRD stock price

How has the Opus Genetics stock price performed over time
Intraday
-6.4%
1 week
-10.72%
1 month
19.26%
1 year
190.96%
YTD
140.3%
QTD
17.52%

Financial performance

How have Opus Genetics's revenue and profit performed over time
Revenue
$9.86M
Gross profit
$9.86M
Operating income
-$50.61M
Net income
-$107.61M
Gross margin
100%
Net margin
-1,091.8%
Opus Genetics's net margin has shrunk by 189% YoY and by 22% QoQ
The company's net income has shrunk by 85% YoY
The operating margin has declined by 43% since the previous quarter and by 22% year-on-year
IRD's gross profit is down by 36% YoY and by 18% QoQ

Price vs fundamentals

How does IRD's price correlate with its fundamentals

Growth

What is Opus Genetics's growth rate over time

Valuation

What is Opus Genetics stock price valuation
P/E
N/A
P/B
N/A
P/S
46.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
35.29
The company's EPS rose by 33% YoY and by 3% QoQ
Opus Genetics's equity has shrunk by 174% YoY but it has surged by 72% QoQ
IRD's P/S is 123% above its last 4 quarters average of 22.4 and 75% above its 5-year quarterly average of 28.5
The revenue is down by 36% year-on-year and by 18% since the previous quarter

Efficiency

How efficient is Opus Genetics business performance
The company's return on sales has shrunk by 188% YoY and by 22% QoQ
IRD's ROA is down by 23% YoY but it is up by 22% from the previous quarter

Dividends

What is IRD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRD.

Financial health

How did Opus Genetics financials performed over time
Opus Genetics's total assets is 12% lower than its total liabilities
Opus Genetics's total assets has surged by 140% YoY and by 39% QoQ
The quick ratio has soared by 77% from the previous quarter
Opus Genetics's equity has shrunk by 174% YoY but it has surged by 72% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.